Hepatitis B vaccine administered to children and adolescents at yearly intervals

Neal A Halsey, Lawrence Hale Moulton, J. Crossan O'Donovan, J. Ronald Walcher, Mary Lou Thoms, Harold S. Margolis, David S. Krause

Research output: Contribution to journalArticle

Abstract

Objective. Hepatitis B vaccines are usually administered on a schedule of 0, 1 to 2, and 6 months. Longer intervals between the second and third doses have been studied, but the effectiveness of hepatitis B vaccine administered at intervals of > 2 months between the first and second doses have not been studied. Our objective was to compare the antibody response in recipients of Engerix-B hepatitis B vaccine administered at 12-month intervals to the response to vaccine administered at 0-, 1-, and 6-month intervals. Methods. A total of 389 children, 5 through 16 years of age, were randomized to receive Engerix-B (10 mg) at a schedule of either 0-, 1-, and 6-month intervals or 0-, 12-, and 24-month intervals. Blood was drawn before and 1 month after the third dose. Results. Immediately before the third dose of vaccine, 92.3% of children who received vaccine on the 0-, 1-, and 6- month schedule and 88.8% of children who received the 0-, 12-, and 24-month schedule had antibody to hepatitis B surface (anti-HBs) antigen concentrations ≥ 10 mIU/mL. Of the children in the 0-, 1-, and 6-month schedule, 95% received the third dose according to protocol versus 90% of those in the 0-, 12-, 24-month schedule. The geometric mean anti-HBs concentration just before the third dose for recipients of the 0-, 1-, and 6- month schedule (117.9 mIU/mL) was somewhat lower than that for the children who had received vaccine on the 0-, 12, and 24-month schedule (162.1 mIU/mL). One month after the third dose, > 98% of all children had anti-HBs concentrations ≥ 10 mIU/mL and high geometric mean antibody concentrations were observed in both group: 5687 mIU/mL for children on the 0-, 1-, and 6- month schedule and 3159 mIU/mL for children on the 0-, 12-, and 24-month schedule. Body mass index was correlated inversely with final antibody concentration, but age was not a factor after adjustment for body mass index. Discussion. Engerix-B administered on a 0-, 12-, and 24-month schedule is highly immunogenic. Providers should consider this alternate immunization schedule for children who are at low risk of immediate exposure to hepatitis B infections.

Original languageEnglish (US)
Pages (from-to)1243-1247
Number of pages5
JournalPediatrics
Volume103
Issue number6 I
DOIs
StatePublished - Jun 1999

Fingerprint

Hepatitis B Vaccines
Appointments and Schedules
Vaccines
Body Mass Index
Immunization Schedule
Hepatitis B Antibodies
Antibodies
Hepatitis B
Antibody Formation

Keywords

  • Adolescent
  • Antigen
  • Dose
  • Hepatitis B
  • Hepatitis B vaccine
  • Immunization
  • Schedule
  • Vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Moulton, L. H., O'Donovan, J. C., Walcher, J. R., Thoms, M. L., Margolis, H. S., & Krause, D. S. (1999). Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics, 103(6 I), 1243-1247. https://doi.org/10.1542/peds.103.6.1243

Hepatitis B vaccine administered to children and adolescents at yearly intervals. / Halsey, Neal A; Moulton, Lawrence Hale; O'Donovan, J. Crossan; Walcher, J. Ronald; Thoms, Mary Lou; Margolis, Harold S.; Krause, David S.

In: Pediatrics, Vol. 103, No. 6 I, 06.1999, p. 1243-1247.

Research output: Contribution to journalArticle

Halsey, NA, Moulton, LH, O'Donovan, JC, Walcher, JR, Thoms, ML, Margolis, HS & Krause, DS 1999, 'Hepatitis B vaccine administered to children and adolescents at yearly intervals', Pediatrics, vol. 103, no. 6 I, pp. 1243-1247. https://doi.org/10.1542/peds.103.6.1243
Halsey, Neal A ; Moulton, Lawrence Hale ; O'Donovan, J. Crossan ; Walcher, J. Ronald ; Thoms, Mary Lou ; Margolis, Harold S. ; Krause, David S. / Hepatitis B vaccine administered to children and adolescents at yearly intervals. In: Pediatrics. 1999 ; Vol. 103, No. 6 I. pp. 1243-1247.
@article{3850e89a4f9f4e9cbe54e8f8cd02bed8,
title = "Hepatitis B vaccine administered to children and adolescents at yearly intervals",
abstract = "Objective. Hepatitis B vaccines are usually administered on a schedule of 0, 1 to 2, and 6 months. Longer intervals between the second and third doses have been studied, but the effectiveness of hepatitis B vaccine administered at intervals of > 2 months between the first and second doses have not been studied. Our objective was to compare the antibody response in recipients of Engerix-B hepatitis B vaccine administered at 12-month intervals to the response to vaccine administered at 0-, 1-, and 6-month intervals. Methods. A total of 389 children, 5 through 16 years of age, were randomized to receive Engerix-B (10 mg) at a schedule of either 0-, 1-, and 6-month intervals or 0-, 12-, and 24-month intervals. Blood was drawn before and 1 month after the third dose. Results. Immediately before the third dose of vaccine, 92.3{\%} of children who received vaccine on the 0-, 1-, and 6- month schedule and 88.8{\%} of children who received the 0-, 12-, and 24-month schedule had antibody to hepatitis B surface (anti-HBs) antigen concentrations ≥ 10 mIU/mL. Of the children in the 0-, 1-, and 6-month schedule, 95{\%} received the third dose according to protocol versus 90{\%} of those in the 0-, 12-, 24-month schedule. The geometric mean anti-HBs concentration just before the third dose for recipients of the 0-, 1-, and 6- month schedule (117.9 mIU/mL) was somewhat lower than that for the children who had received vaccine on the 0-, 12, and 24-month schedule (162.1 mIU/mL). One month after the third dose, > 98{\%} of all children had anti-HBs concentrations ≥ 10 mIU/mL and high geometric mean antibody concentrations were observed in both group: 5687 mIU/mL for children on the 0-, 1-, and 6- month schedule and 3159 mIU/mL for children on the 0-, 12-, and 24-month schedule. Body mass index was correlated inversely with final antibody concentration, but age was not a factor after adjustment for body mass index. Discussion. Engerix-B administered on a 0-, 12-, and 24-month schedule is highly immunogenic. Providers should consider this alternate immunization schedule for children who are at low risk of immediate exposure to hepatitis B infections.",
keywords = "Adolescent, Antigen, Dose, Hepatitis B, Hepatitis B vaccine, Immunization, Schedule, Vaccine",
author = "Halsey, {Neal A} and Moulton, {Lawrence Hale} and O'Donovan, {J. Crossan} and Walcher, {J. Ronald} and Thoms, {Mary Lou} and Margolis, {Harold S.} and Krause, {David S.}",
year = "1999",
month = "6",
doi = "10.1542/peds.103.6.1243",
language = "English (US)",
volume = "103",
pages = "1243--1247",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6 I",

}

TY - JOUR

T1 - Hepatitis B vaccine administered to children and adolescents at yearly intervals

AU - Halsey, Neal A

AU - Moulton, Lawrence Hale

AU - O'Donovan, J. Crossan

AU - Walcher, J. Ronald

AU - Thoms, Mary Lou

AU - Margolis, Harold S.

AU - Krause, David S.

PY - 1999/6

Y1 - 1999/6

N2 - Objective. Hepatitis B vaccines are usually administered on a schedule of 0, 1 to 2, and 6 months. Longer intervals between the second and third doses have been studied, but the effectiveness of hepatitis B vaccine administered at intervals of > 2 months between the first and second doses have not been studied. Our objective was to compare the antibody response in recipients of Engerix-B hepatitis B vaccine administered at 12-month intervals to the response to vaccine administered at 0-, 1-, and 6-month intervals. Methods. A total of 389 children, 5 through 16 years of age, were randomized to receive Engerix-B (10 mg) at a schedule of either 0-, 1-, and 6-month intervals or 0-, 12-, and 24-month intervals. Blood was drawn before and 1 month after the third dose. Results. Immediately before the third dose of vaccine, 92.3% of children who received vaccine on the 0-, 1-, and 6- month schedule and 88.8% of children who received the 0-, 12-, and 24-month schedule had antibody to hepatitis B surface (anti-HBs) antigen concentrations ≥ 10 mIU/mL. Of the children in the 0-, 1-, and 6-month schedule, 95% received the third dose according to protocol versus 90% of those in the 0-, 12-, 24-month schedule. The geometric mean anti-HBs concentration just before the third dose for recipients of the 0-, 1-, and 6- month schedule (117.9 mIU/mL) was somewhat lower than that for the children who had received vaccine on the 0-, 12, and 24-month schedule (162.1 mIU/mL). One month after the third dose, > 98% of all children had anti-HBs concentrations ≥ 10 mIU/mL and high geometric mean antibody concentrations were observed in both group: 5687 mIU/mL for children on the 0-, 1-, and 6- month schedule and 3159 mIU/mL for children on the 0-, 12-, and 24-month schedule. Body mass index was correlated inversely with final antibody concentration, but age was not a factor after adjustment for body mass index. Discussion. Engerix-B administered on a 0-, 12-, and 24-month schedule is highly immunogenic. Providers should consider this alternate immunization schedule for children who are at low risk of immediate exposure to hepatitis B infections.

AB - Objective. Hepatitis B vaccines are usually administered on a schedule of 0, 1 to 2, and 6 months. Longer intervals between the second and third doses have been studied, but the effectiveness of hepatitis B vaccine administered at intervals of > 2 months between the first and second doses have not been studied. Our objective was to compare the antibody response in recipients of Engerix-B hepatitis B vaccine administered at 12-month intervals to the response to vaccine administered at 0-, 1-, and 6-month intervals. Methods. A total of 389 children, 5 through 16 years of age, were randomized to receive Engerix-B (10 mg) at a schedule of either 0-, 1-, and 6-month intervals or 0-, 12-, and 24-month intervals. Blood was drawn before and 1 month after the third dose. Results. Immediately before the third dose of vaccine, 92.3% of children who received vaccine on the 0-, 1-, and 6- month schedule and 88.8% of children who received the 0-, 12-, and 24-month schedule had antibody to hepatitis B surface (anti-HBs) antigen concentrations ≥ 10 mIU/mL. Of the children in the 0-, 1-, and 6-month schedule, 95% received the third dose according to protocol versus 90% of those in the 0-, 12-, 24-month schedule. The geometric mean anti-HBs concentration just before the third dose for recipients of the 0-, 1-, and 6- month schedule (117.9 mIU/mL) was somewhat lower than that for the children who had received vaccine on the 0-, 12, and 24-month schedule (162.1 mIU/mL). One month after the third dose, > 98% of all children had anti-HBs concentrations ≥ 10 mIU/mL and high geometric mean antibody concentrations were observed in both group: 5687 mIU/mL for children on the 0-, 1-, and 6- month schedule and 3159 mIU/mL for children on the 0-, 12-, and 24-month schedule. Body mass index was correlated inversely with final antibody concentration, but age was not a factor after adjustment for body mass index. Discussion. Engerix-B administered on a 0-, 12-, and 24-month schedule is highly immunogenic. Providers should consider this alternate immunization schedule for children who are at low risk of immediate exposure to hepatitis B infections.

KW - Adolescent

KW - Antigen

KW - Dose

KW - Hepatitis B

KW - Hepatitis B vaccine

KW - Immunization

KW - Schedule

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0033038666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033038666&partnerID=8YFLogxK

U2 - 10.1542/peds.103.6.1243

DO - 10.1542/peds.103.6.1243

M3 - Article

C2 - 10353936

AN - SCOPUS:0033038666

VL - 103

SP - 1243

EP - 1247

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6 I

ER -